Skip to main content

Table 1 Baseline characteristics

From: Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial

Variables Ivermectin (N = 250) Placebo (N = 251)
Demographic characteristics
 Age years, mean (±SD) 42.58 (15.29) 42.40 (15.75)
  < 65 years, N (%) 229 (91.6) 231 (92.03)
 Weight Kg, mean (±SD) 81.708 (18.507) 81.313 (18.273)
 Dose μg/Kg/day, mean (±SD) 192.37 (24.56) 190.61 (23.93)
 Women, N (%) 111 (44.4) 126 (50.2)
 Hypertension, N (%) 53 (21.3) 66 (26.3)
 Diabetes mellitus, N (%) 21 (8.4) 27 (10.8)
 Smoker, N (%) 27 (10.8) 25 (10.0)
 Former smoker, N (%) 72 (28.9) 71 (28.3)
 Asthma, N (%) 16 (6.4) 20 (8.0)
 COPD, N (%) 7 (2.8) 7 (2.8)
 Previous myocardial infarction, N (%) 3 (1.2) 6 (2.4)
 Previous coronary angioplasty, N (%) 3 (1.2) 1 (0.4)
 Previous stroke, N (%) 1 (0.4) 4 (1.6)
 Heart failure, N (%) 1 (0.4) 3 (1.2)
 Cancer, N (%) 4 (1.6) 2 (0.8)
 Previous cancer, N (%) 6 (2.4) 4 (1.6)
 Any comorbidity, N (%) 143 (57.66) 149 (59.84)
Symptoms / Swabs
 Symptomatic by COVID-19, N (%) 240 (96.0) 241 (96.0)
 Days from symptoms started to inclusion, median (IQR) 4 (3–5) 4 (3–6)
 Days from inclusion to swab 1, mean (±SD) 3.26 (0.66) 3.30 (0.71)
 Days from inclusion to swab 2, mean (±SD) 9.99 (1.56) 10.13 (1.69)
Previous treatment
 Beta blockers, N (%) 17 (6.8) 21 (8.4)
 ACEI, N (%) 13 (5.2) 16 (6.4)
 ARB, N (%) 28 (11.2) 36 (14.3)
 Aspirin, N (%) 14 (5.6) 19 (7.6)
 Statins, N (%) 22 (8.8) 16 (6.4)
 Puff inhalation, N (%) 10 (4.0) 11 (4.4)
 Corticosteroids, N (%) 12 (4.8) 11 (4.4)
Laboratory values
 Hematocrit %, mean (±SD) 44.63 (5.12) 43.29 (4.90)
 Hemoglobin g/dL, mean (±SD) 14.79 (1.79) 14.32 (1.73)
 White blood count, mean (±SD) 5931.33 (1952.79) 5550.96 (1778.07)
 Platelets /μL, mean (±SD) 232,394.38 (66,306.41) 222,032 (64,476.13)
 Creatinine mg/dL, mean (±SD) 0.79 (0.25) 0.81 (0.28)
 Urea g/L, median (IQR) 0.30 (0.24–0.37) 0.30 (0.24–0.38)
 AST U/L, median (IQR) 27 (21–39) 27 (20–41)
 ALT U/L, median (IQR) 31 (18–50) 29 (18–52)
 Alkaline phosphatase U/L, median (IQR) 187 (151–234) 187 (153.5–243.5)
 Total bilirrubin mg/dL, median (IQR) 0.30 (0.20–0.42) 0.30 (0.20–0.42)
Vital signs
 V#1 Heart rate b/m, mean (±SD) 83.18 (13.64) 82.29 (13.41)
 V#1 Oxygen saturation %, mean (±SD) 96.09 (3.16) 96.31 (2.01)
 V#1 Axillary temperature °C, mean (±SD) 36.15 (0.84) 36.09 (0.80)
 V#2 Heart rate b/m, mean (±SD) 82.05 (12.65) 83.29 (13.35)
 V#2 Oxygen saturation %, mean (±SD) 96.13 (2.28) 96.04 (2.42)
 V#2 Axillary temperature °C, mean (±SD) 35.99 (0.75) 36.03 (0.77)
  1. SD standard deviation; Kg kilograms; μg/Kg/day micrograms/kilogram/day; COPD: chronic obstructive pulmonary disease; COVID-19 coronavirus disease 19; IQR interquartile range; ACEI angiotensin converting enzyme inhibitors; ARB angiotensin receptor blockers; g/dL grams/deciliter; μL microliter; mg/dL milligrams/deciliter; g/L grams/liter; U/L units/liter; V# visit number; b/m beats/minute; °C Celsius degrees; V#1: day 0; V#2: day 3.